Hyderabad-based Biological E Limited will infuse an additional Rs 250 crore into its recently-commissioned biopharmaceutical and vaccine manufacturing campus over the next three years.
The 75-acre campus, located in phase-II of SP Biotech Park at Shameerpet on the outskirts of Hyderabad, was set up at an investment of over Rs 300 crore. The facility will manufacture vaccines and biopharmaceuticals that are crucial in the global effort to prevent childhood diseases. These products are intended for supply to markets worldwide, including the US and Europe, through the company's strategic partners.
“We expect to further invest in the new campus in the next two to three years in expanding capacities and creating infrastructure for the future pipeline of products,” the company stated in a press release on Monday.
Biological E, established in 1953, manufactures a range of biologics and vaccines including tetanus (TT), diphtheria-tetanus-pertussis (DTwP), hepatitis B and haemophilus influenza type B.